Celgosivir hydrochloride

• CAT Number: I013700
• CAS Number: 141117-12-6
• Molecular Formula: C₁₂H₂₂ClNO₅
• Molecular Weight: 295.76
• Purity: ≥95%
• Target: HCVHIV
• Solubility: H2O: ≥ 200 mg/mL
• IUPAC Name: [(1S,6S,7S,8R,8aR)-1,7,8-trihydroxy-1,2,3,5,6,7,8,8a-octahydroindolizin-6-yl] butanoate;hydrochloride
• InChI: InChI=1S/C12H21NO5.ClH/c1-2-3-9(15)18-8-6-13-5-4-7(14)10(13)12(17)11(8)16;/h7-8,10-12,14,16-17H,2-6H2,1H3;1H/t7-,8-,10+,11+,12+;/m0./s1
• InChIKey: KXNZMBFOWDNCRU-QVMZSJACSA-N
• SMILES: CCCC(=O)OC1CN2CCC(C2C(C1O)O)O.Cl

Celgosivir hydrochloride (Cat.No:I013700) is an antiviral drug that inhibits the replication of viruses such as dengue virus, West Nile virus, and hepatitis C virus. It works by blocking the enzyme α-glucosidase, which is necessary for the virus to replicate. Celgosivir hydrochloride has shown promising results in clinical trials for the treatment of dengue fever and hepatitis C. However, further studies are needed to determine its effectiveness and safety for use in humans.

Reference

[1]. Taylor DL, et al. Inhibition of alpha-glucosidase I of the glycoprotein-processing enzymes by 6-O-butanoylcastanospermine (MDL 28,574) and its consequences in human immunodeficiency virus-infected T cells. Antimicrob Agents Chemother. 1994 Aug;38(8):1780-7.[2]. Whitby K, et al. Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV: implications for the treatment of hepatitis C. Antivir Chem Chemother. 2004 May;15(3):141-51.[3]. Watanabe S, et al. Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial. Antiviral Res. 2012 Oct;96(1):32-5. [4]. Rathore AP, et al. Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes andprotects against lethal challenge mouse model. Antiviral Res. 2011 Dec;92(3):453-60.